menu
Manufacturing
May 7, 2021

Exeliom Biosciences opens pilot manufacturing unit for Live Biotherapeutics (LBPs) thanks to European H2020 Accelerator Program

We have reached a very exciting milestone!

We have just opened our own pilot manufacturing unit to boost our R&D efforts!

€2.5 million was the amount granted by the European Innovation Council and SMEs Executive Agency (EISMEA)'s H2020 Accelerator Program notably to support the set up of this state-of-the-art pilot unit. We also gladly benefited from the logistical support of our historical partner INRAE.

It is a major step in establishing Exeliom Biosciences as a leading player in the field of microbiome-based therapeutics.

Back to news
#Faecalibacterium #GutHealth #HealthResearch #Microbiome #Biotherapeutics #Biotech
Sep 21, 2023
New review on Faecalibacterium published in FEMS Microbiology Reviews explores its potential for human health
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences

contact

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.